Hanyu Pharmaceutical Co., Ltd. has accepted the raw materials and preparations of ticlopeptide and nesiritide

According to the website of the State Food and Drug Administration (CFDA) on March 27, Hanyu Pharmaceutical Co., Ltd centrally applied for the acceptance of the three kinds of clinical drugs, i.e the raw materials and preparations of ticarciptide and nesiritide, to further reserve varieties of polypeptide drugs for the company Nesiritide and nesiritide for injection are cardiovascular drugs They are recombinant human B-type natriuretic peptide developed by scios company of the United States They are mainly used for the treatment of dyspnea in acute decompensated congestive heart failure Another declared variety, ticlopidine and ticlopidine zinc suspension injection, belongs to the category of endocrine drugs, which can stimulate the adrenal cortex to secrete corticosteroids Hanyu Pharmaceutical Co., Ltd is the first listed company dealing in polypeptide drugs in China, with the market share ranking top three The company's polypeptide preparations mainly include thymopentin for injection, somatostatin for injection and deammopressin acetate injection According to the 2013 annual report, the company's main business income was 301 million yuan, an increase of 33.37% year on year, and the net profit attributable to shareholders of the listed company was 129 million yuan, an increase of 44.69% year on year During the period, the company's main polypeptide preparation revenue reached 269 million yuan, an increase of 29.47%, accounting for nearly 90% of the main revenue